drugset / Trial / NCT01809223

A Randomized, Double-blind, Multicenter, Sham-controlled, Safety and Efficacy Study of Conbercept in Patients With mCNV

NCT01809223

Phase 3 Unknown 176 enrolled Chengdu Kanghong Biotech Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is design to evaluate the effect of conbercept therapy on visual acuity and anatomic outcomes compared to sham injection and durability of response observed in subjects with choroid neovascularization secondary to pathological myopia.

Timeline

Start
2012-08
Primary completion
2014-02
Completion
2015-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Conbercept Protein / enzyme biologic 0.5 mg Intravitreal